Literature DB >> 19764027

Progressive neurocognitive decline in two children with Dravet syndrome, de novo SCN1A truncations and different epileptic phenotypes.

Daria Riva1, Chiara Vago, Chiara Pantaleoni, Sara Bulgheroni, Massimo Mantegazza, Silvana Franceschetti.   

Abstract

Dravet syndrome, often caused by mutations of SCN1A-gene, presents with prolonged clonic, generalized or unilateral seizures often occurring with fever during the first year of life, followed by usually severe epilepsy. The EEG, normal at the outset, later shows generalized and focal epileptic activities. The psychomotor development deteriorates, but little is known about the time course of the cognitive impairment and its relationship with seizures severity. We describe here the progressive neurocognitive decline in two children (one male), carrying de novo SCN1A truncating mutations and presenting with different epileptic phenotypes. The children were longitudinally assessed from the ages of 11 and 23 months until the age of 7 and 8 years, using the same scales to measure the developmental competence in various domains. Both had seizures during the first year of life, unilateral clonic in one and myoclonic in the other, but the subsequent epilepsy severity and the characteristics of the EEG diverged. One child had drug-resistant but rare generalized seizures and isolated EEG spike-wave paroxysms, while the other developed extremely frequent clusters of polymorphic seizures and generalized plus multifocal EEG epileptic activities. MRI was normal in both. A clear developmental delay begun before the age of 2 years in both children and the cognitive profile continued to worse, with some differences between different domains, irrespectively to the different course of their epileptic histories. Our observations are consistent with the hypothesis that SCN1A-mutations can be responsible not only for epilepsy, but also for early and progressive severe mental impairment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19764027     DOI: 10.1002/ajmg.a.33029

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  5 in total

Review 1.  Voltage-gated Sodium Channels and Blockers: An Overview and Where Will They Go?

Authors:  Zhi-Mei Li; Li-Xia Chen; Hua Li
Journal:  Curr Med Sci       Date:  2019-12-16

Review 2.  Pharmacotherapy for Dravet Syndrome.

Authors:  Adam Wallace; Elaine Wirrell; Daniel L Kenney-Jung
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

Review 3.  Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy.

Authors:  Lori L Isom; Kelly G Knupp
Journal:  Neurotherapeutics       Date:  2021-08-10       Impact factor: 6.088

4.  Identification of SCN1A and PCDH19 mutations in Chinese children with Dravet syndrome.

Authors:  Anna Ka-Yee Kwong; Cheuk-Wing Fung; Siu-Yuen Chan; Virginia Chun-Nei Wong
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

5.  Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy.

Authors:  Rima Nabbout; Nicole Chemaly; Mathilde Chipaux; Giulia Barcia; Charles Bouis; Celia Dubouch; Dorothee Leunen; Isabelle Jambaqué; Olivier Dulac; Georges Dellatolas; Catherine Chiron
Journal:  Orphanet J Rare Dis       Date:  2013-11-13       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.